Having trouble reading this email? View the web version here \| Forward this email to a colleague

Cambridge-Elan Centre for Research Innovation and Drug Discovery launched

The University of Cambridge and Elan Corporation plc.(NYSE: ELN) have announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England.

The Cambridge-Elan Centre will provide a highly interdisciplinary environment uniquely positioned for delivering world-leading translational research focused on innovative therapies for Alzheimer’s and Parkinson’s diseases...

Read the full story >>

More pharmaceutical & life science news:

		KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes AstraZeneca and Bristol-Myers Squibb Company have announced that the European Commission has granted marketing authorisation for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination)...

		ONGLYZA® (saxagliptin) approved for use in Europe as combination therapy with insulin in adults with type 2 diabetes Bristol-Myers Squibb Company and AstraZeneca have announced that the European Commission has approved ONGLYZA® (saxagliptin)...

		AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures AstraZeneca have announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million...

		Novartis gains European Commission approval for Rasitrio® Novartis have announced that Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide (HCT) in a single pill, has received approval from the European Commission (EC) for the treatment of high blood pressure...

		Abbott expands agreement with GSK to include development of a companion diagnostic test for an additional investigational cancer immunotherapy antigen Abbott have announced that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program...

		Gilead receives European marketing authorization for Eviplera® Gilead Sciences, Inc. have announced that the European Commission has granted marketing authorization for Eviplera® (emtricitabine/rilpivirine/tenofovir disoproxil)...

		A drug for Type 1 diabetes meets primary and secondary goals of Phase III clinical trials The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial...

		Pfizer to acquire Excaliard Pharmaceuticals Pfizer Inc. and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring...

Events, conferences & exhibitions:

Analytical Method Validation for Biologics, Biopharmaceuticals and Other Therapeutic Products
1 - 2 December 2011, Dublin, Ireland

Stability Programs for Product Shelf Life – From Development to Approval
5 - 6 December 2011, Berlin, Germany

Active Pharmaceutical Ingredients (API) and Drug Product Specifications
7 - 9 December 2011, Berlin, Germany

Pharmaceutical Expo 2011
16 - 18 December 2011, Bangalore, India

High Content Analysis 2012
10 - 13 January 2012, San Francisco, CA, USA

IFPAC 2012
22 - 25 January 2012, Baltimore, USA

SLAS 2012
4 - 8 February 2012 San Diego, CA, USA

Drug Discovery for Neurodegeneration
12 - 14 February 2012 New York, USA

4th International Conference on Drug Discovery and Therapy
12 - 15 February 2012 Dubai, UAE

9th Annual PAT and Quality by Design
20 - 22 February 2012 London, UK

The New Health is data driven. Biopharma is swimming in oceans of data, and it’s still growing exponentially. Quintiles is introducing a singular way to aggregate, harmonize and gain insights from your data. Quintiles Infosario™ is a new platform that allows you to view data from multiple sources—sites, labs, ECG, finance, HR and more—all in one place. So you can make better decisions, faster.

Learn how Quintiles can help you move from information to insights—and from insights to outcomes. Watch From Information to Insight at quintiles.com/newhealth

Featured whitepaper

Utilizing Colony-Forming Cell Assays In Toxicity Testing

To decrease the cost and time invested in drug development, efforts must be made to improve the chances of a compound successfully completing clinical trials. Validated CFU-GM assays have successfully predicted MTDs in humans and have bridged the gap between in vitro screening technologies and in vivo studies. Using CFC assays to obtain information on the hematological effects of a new drug is a quick and cost-effective way to make more informed decisions concerning progression through the drug pipeline.

Download the whitepaper >>

Company directory

Our new look directory includes hundreds of organisations, plus the following Premium listings:

- ABB Analytical Measurements
- Almac
- BD Diagnostics
- Bio-Optronics, Inc.
- bioMérieux
- BioTek Instruments, Inc.
- BMG LABTECH GmbH
- Bruker Daltonik GmbH
- CAMO Software AS
- CI Precision
- Cisbio Bioassays
- Colder Products Company
- DCA Design International
- DiscoveRx Corporation
- Expo Technologies, LLC.
- Freeman Technology
- GE Analytical Instruments
- HACH LANGE GMBH
- HORIBA Scientific
- Hudson Robotics, Inc.
- IDBS
- Natoli Engineering Company, Inc.
- Peter Huber Kältemaschinenbau
- Randox Pharma Services
- Rapid Micro Biosystems
- Sapient Discovery
- Smithers Viscient
- Synbiosis
- Syngene
- TOPRA
- Watson-Marlow Pumps Group

Add your company >>

Join European Pharmaceutical Review on LinkedIn

Follow European Pharmaceutical Review on Twitter

Like European Pharmaceutical Review on Facebook